ClinicalTrials.gg
RecruitingNCT06479343Updated Sep 19, 2024

Efficacy and Safety of the Liquid Embolic System (Tonbridge) for Endovascular Treatment of Cerebrovascular Malformations

An interventional study of Liquid Embolic System (Tonbridge) and Onyx Liquid Embolic System (Medtronic) in Intracranial Arteriovenous Malformations, sponsored by Zhuhai Tonbridge Medical Tech. Co., Ltd.. Recruiting at 14 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Zhuhai Tonbridge Medical Tech. Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Intracranial Arteriovenous Malformations with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Intracranial Arteriovenous Malformations · China.

Started
2024
the only one that year
No phase
4 of 13
1 open now
Registered
10th of 13
by date
Lead sponsor
1 of 13
Zhuhai Tonbridge Medical Tech. Co., Ltd.

Among the 13 studies in Intracranial Arteriovenous Malformations with a site in China, this one is the only one that started in 2024, is one of 4 with no phase, and was the 10th registered.

Intracranial Arteriovenous Malformations

43 studies on the registry are indexed under Intracranial Arteriovenous Malformations; 15 are open to participants now.

Browse Intracranial Arteriovenous Malformations studies →

Open to participants now

4 of the 13 studies in Intracranial Arteriovenous Malformations with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 13 Intracranial Arteriovenous Malformations studies recruiting now, 10 (77%) set no upper age limit and 2 (15%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Intracranial Arteriovenous Malformations with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to verify the efficacy and safety of the Liquid Embolic System (Tonbridge Medical Tech. Co., Ltd. (Suzhou)) for the treatment of cerebrovascular malformations.

Read the detailed description

This is a prospective, multi-center, randomized, parallel positive controlled, non-inferiority trial. This clinical trial is conducted at more than 2 centers in China, and patients who intend to be treated with liquid embolic system for cerebrovascular malformations are enrolled. Eligible patients are randomized into experimental group using Liquid Embolic System (Tonbridge) or control group using Onyx Liquid Embolic System (Medtronic) in a 1:1 ratio. The purpose of this study is to evaluate the effectiveness and safety of the Liquid Embolic System (Tonbridge).

03

Conditions studied

  • Intracranial Arteriovenous Malformations
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 80 years, any gender;
  • Subject is suitable for endovascular treatment of cerebrovascular malformations;
  • Subject is able to understand the purpose of the study, shows sufficient compliance with the study protocol and provides a signed form.

Exclusion criteria

Exclusion Criteria:

  • Intracranial hemorrhage within 1 month prior to treatment;
  • The targeted embolization area needs to receive other treatments (surgical resection, SRS, other embolic materials) at the same time;
  • Combination of other cerebrovascular malformations, such as cavernous vascular malformation;
  • Severe stenosis or occlusion of cerebral feeding artery requiring surgical intervention;
  • Intracranial tumor requiring surgical intervention;
  • mRS score≥3;
  • Heart, lung, liver and renal failure or other severe diseases;
  • Known bleeding tendency, such as coagulation dysfunction (>1.5);
  • Known allergy to DMSO and contrast media, or to anticoagulant therapy;
  • Pregnant or breastfeeding women, or who plan to become pregnant during the study;
  • Subject is participating in other drug or medical device clinical trials at the time of signing ;
  • Other conditions judged by the investigators as unsuitable for enrollment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Liquid Embolic System (Tonbridge)

    Device: Liquid Embolic System (Tonbridge)

  • Active comparator
    Onyx Liquid Embolic System (Medtronic)

    Device: Onyx Liquid Embolic System (Medtronic)

Interventions

  • DeviceLiquid Embolic System (Tonbridge)

    Endovascular treatment with Liquid Embolic System (Tonbridge).

  • DeviceOnyx Liquid Embolic System (Medtronic)

    Endovascular treatment with Onyx Liquid Embolic System (Medtronic).

06

What researchers measure

Primary outcomes

  1. Targeted Embolization Satisfaction Rate

    Targeted embolization satisfaction is defined as achieving ≥50% occlusion of the targeted embolized area after treatment with liquid embolic system, which is determined by immediate postoperative cerebrovascular DSA.

    Time frame: intra-procedure

Secondary outcomes

  1. mRS score

    mRS scores are assessed at each evaluation time point.

    Time frame: 1 month±7 days, 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure

  2. GOS score

    GOS scores are assessed at each evaluation time point.

    Time frame: 1 month±7 days, 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure

  3. Operation satisfaction rate

    The 5-point Likert scale is used to evaluate operation satisfaction from three aspects: visualization, diffusion, and microcatheter withdrawal. "Operation satisfaction rate" is defined as the proportion of investigational devices or comparators with Likert score≥12 points.

    Time frame: intra-procedure

  4. Incidence of major adverse events (MAEs)

    MAEs are defined as intracranial hemorrhage and ischemic complications. Intracranial hemorrhage included intraoperative hemorrhage (puncture of blood-supplying arteries by catheters or guidewires, rupture of nidus, and injury to blood vessels during withdrawal of catheters) and delayed symptomatic hemorrhage in the postoperative period; and ischemic complications included intraoperative ischemic complications (displacement of liquid embolic agents, thrombosis, and so on) and postoperative symptomatic ischemic stroke. "Incidence of major adverse events" is the proportion of subjects with adverse events using the investigational device or the comparator.

    Time frame: 1 month±7 days, 3 months±30 days post-procedure

  5. Incidence of adverse events (AEs)

    "Incidence of adverse events" is the proportion of subjects with adverse events using the investigational device or the comparator.

    Time frame: 1 month±7 days, 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure

  6. Incidence of serious adverse events (SAEs)

    "Incidence of serious adverse events" is the proportion of subjects with serious adverse events using the investigational device or the comparator.

    Time frame: 1 month±7 days, 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure

  7. Incidence of device deficiency

    Device deficiency is the unreasonable risk that may endanger human health and life safety in the normal use of medical devices during clinical trials, such as labeling errors, quality problems and malfunctions.

    Time frame: 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure

07

Study locations

2 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Oct 2025, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2024
First posted
Jun 28, 2024
StartActual
Jun 27, 2024
Primary completionEst.
Oct 2025
CompletionEst.
Oct 2026
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06479343
Lead sponsor
Zhuhai Tonbridge Medical Tech. Co., Ltd.
Responsible party
Sponsor
First posted
Jun 28, 2024
Start date
Jun 27, 2024
Primary completion
Oct 2025 (estimated)
Completion
Oct 2026 (estimated)
Last update
Sep 19, 2024

Study contacts

Jing Pan
Contact
jing.pan@ton-bridge.com
18916099975
Jin Zheng
Contact
Peng Zhang
principal investigator · Xuanwu Hospital, Beijing

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion